UBS Group’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-1,101,275
| Closed | -$22.2M | – | 11245 |
|
|
2021
Q3 | $22.2M | Sell |
1,101,275
-234,545
| -18% | -$6.48M | 0.01% | 1427 |
|
|
2021
Q2 | $49.9M | Sell |
1,335,820
-42,803
| -3% | -$1.31M | 0.02% | 856 |
|
|
2021
Q1 | $35.3M | Sell |
1,378,623
-821,864
| -37% | -$21M | 0.01% | 1051 |
|
|
2020
Q4 | $48.5M | Buy |
2,200,487
+1,112,278
| +102% | +$24.5M | 0.02% | 805 |
|
|
2020
Q3 | $19.6M | Sell |
1,088,209
-262,068
| -19% | -$5.43M | 0.01% | 1182 |
|
|
2020
Q2 | $34.3M | Sell |
1,350,277
-806,912
| -37% | -$17.4M | 0.01% | 785 |
|
|
2020
Q1 | $39.6M | Sell |
2,157,189
-33,077
| -2% | -$643K | 0.02% | 649 |
|
|
2019
Q4 | $48.3M | Sell |
2,190,266
-244,273
| -10% | -$4.92M | 0.02% | 801 |
|
|
2019
Q3 | $35M | Sell |
2,434,539
-33,260
| -1% | -$475K | 0.01% | 882 |
|
|
2019
Q2 | $38.9M | Buy |
2,467,799
+48,678
| +2% | +$662K | 0.02% | 795 |
|
|
2019
Q1 | $35.4M | Buy |
2,419,121
+1,679,033
| +227% | +$19.3M | 0.01% | 817 |
|
|
2018
Q4 | $7.91M | Buy |
740,088
+234,497
| +46% | +$3.08M | ﹤0.01% | 1770 |
|
|
2018
Q3 | $7.71M | Sell |
505,591
-101,408
| -17% | -$1.48M | ﹤0.01% | 1986 |
|
|
2018
Q2 | $7.44M | Buy |
606,999
+5,177
| +0.9% | +$65K | ﹤0.01% | 1978 |
|
|
2018
Q1 | $5.75M | Sell |
601,822
-10,305
| -2% | -$111K | ﹤0.01% | 2174 |
|
|
2017
Q4 | $5.53M | Sell |
612,127
-2,890
| -0.5% | -$21.3K | ﹤0.01% | 2259 |
|
|
2017
Q3 | $3.54M | Buy |
615,017
+331,084
| +117% | +$1.2M | ﹤0.01% | 2557 |
|
|
2017
Q2 | $900K | Sell |
283,933
-712
| -0.3% | -$2.25K | ﹤0.01% | 3709 |
|
|
2017
Q1 | $968K | Buy |
284,645
+1,599
| +0.6% | +$4.5K | ﹤0.01% | 3555 |
|
|
2016
Q4 | $815K | Buy |
283,046
+17,271
| +6% | +$61.4K | ﹤0.01% | 3725 |
|
|
2016
Q3 | $1.56M | Buy |
265,775
+259,400
| +4,069% | +$909K | ﹤0.01% | 3066 |
|
|
2016
Q2 | $19K | Buy |
+6,375
| New | +$26.2K | ﹤0.01% | 6361 |
|
|
2016
Q1 | – | Sell |
-242
| Closed | -$3K | – | 8394 |
|
|
2015
Q4 | $3K | Sell |
242
-1,047
| -81% | -$12K | ﹤0.01% | 7920 |
|
|
2015
Q3 | $11K | Buy |
1,289
+289
| +29% | +$3.34K | ﹤0.01% | 7218 |
|
|
2015
Q2 | $14K | Sell |
1,000
-1,715
| -63% | -$31.5K | ﹤0.01% | 7208 |
|
|
2015
Q1 | $65K | Buy |
+2,715
| New | +$61.1K | ﹤0.01% | 5802 |
|
Other funds holding DRNA
UBS Group's DRNA Position: Q4 2021 in Review
UBS Group sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 1,101,275 shares — an estimated $22.2M sold.
UBS Group first reported a position in DRNA in Q1 2015 and held it in 26 quarters. The position peaked at $49.9M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.
- UBS Group reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
- UBS Group sold 1,101,275 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $22.2M.
- UBS Group first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2015 and held it in 26 quarters.
- UBS Group's Dicerna Pharmaceuticals, Inc. position peaked at $49.9M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.
Based on UBS Group's 13F filing for Q4 2021, filed 14 Feb 2022.